Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2027, 2028, and 2029 (P50 Clinical Trial Required)
This grant funds research centers to conduct innovative, translational studies aimed at improving prevention, detection, diagnosis, and treatment of specific or related human cancers, requiring clinical trials.
Funder: National Institutes of Health (NIH)
Due Dates: January 25, 2027
Funding Amounts: Estimated total program funding: $25,000,000; approximately 12 awards; typical project period up to 5 years.
Summary: Supports translational research centers (SPOREs) focused on prevention, detection, diagnosis, and treatment of organ-specific or mechanistically related human cancers.
Key Information: Clinical trial required; forecasted opportunity—dates subject to change.
Description
This opportunity, administered by the National Cancer Institute (NCI) under the NIH, funds P50 Specialized Programs of Research Excellence (SPORE) grants. The program supports state-of-the-art, investigator-initiated translational research centers dedicated to improving prevention, early detection, diagnosis, and treatment of either an organ-specific cancer or a highly related group of cancers. Eligible groups may include cancers from the same organ system, those driven by a common biological mechanism, or cross-cutting themes such as pediatric cancers or epigenetics. Projects must use human biology research approaches (cellular, molecular, structural, biochemical, and/or genetic) and are required to reach a translational human endpoint during the grant period. Clinical trials are required as part of the funded research.
